Precision BioSciences, Inc. (NASDAQ:DTIL) Earnings Report Analysis

• Earnings per Share (EPS) of -$2.735 was below the estimated EPS of -$2.09.
• DTIL's debt-to-equity ratio is 0.47, suggesting a moderate level of debt relative to equity.

Precision BioSciences, Inc. (NASDAQ:DTIL) is a clinical-stage gene editing company that focuses on developing in vivo gene editing therapies using its proprietary ARCUS® platform. On March 26, 2025, DTIL reported an earnings per share (EPS) of -$2.735, which was below the estimated EPS of -$2.09. The company's actual revenue was $3.471 million, falling short of the estimated revenue of $4.275 million.

DTIL's price-to-sales ratio is 0.53, which means the market values the company's sales at just over half of its current market price. This could imply that investors are cautious about the company's ability to generate revenue in the future. Additionally, the enterprise value to sales ratio is negative at -0.38, indicating that the company's liabilities exceed its market capitalization and cash.

The enterprise value to operating cash flow ratio is 0.59, reflecting the company's ability to generate cash relative to its enterprise value. This suggests that DTIL is relatively efficient in generating cash from its operations.

DTIL's debt-to-equity ratio is 0.47, indicating a moderate level of debt relative to equity. This suggests that the company is not overly reliant on debt to finance its operations. Additionally, DTIL has a strong current ratio of 9.22, suggesting a robust ability to cover its short-term liabilities with its short-term assets.